>哥伦比亚胃癌药物市场，按类型（腺癌、胃肠道间质瘤、类癌瘤、淋巴瘤等）、分期（III 期、II 期、IV 期、I 期等）、治疗（化疗、靶向治疗、免疫检查点抑制剂等）、给药途径（肠胃外、口服等）、最终用户（医院、专科诊所、研究和学术机构等）、分销渠道（医院药房、零售药房等）划分的行业趋势和预测（至 2029 年）
市场分析和见解：哥伦比亚胃癌药物市场
哥伦比亚胃癌药物市场预计将在 2022 年至 2029 年的预测期内获得显着增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场以 8.5% 的复合年增长率增长，预计到 2029 年将达到 4773 万美元。胃肠道肿瘤、淋巴瘤和腺癌病例的增加增加了对药物和治疗的需求，预计将推动胃癌药物市场的增长。
胃癌是一种在胃壁中形成恶性（癌症）细胞的疾病。年龄、饮食和胃病会影响患胃癌的风险。胃癌的症状包括消化不良和胃部不适或疼痛。胃癌往往在多年内缓慢发展。在真正的癌症发展之前，胃内壁（粘膜）通常会在癌症完全发展之前发生癌前病变。这些早期变化很少引起症状，因此经常未被发现。癌症在胃的不同部位发展会引起不同的症状，并且往往会有不同的结果。其位置也会影响治疗方案。
预计胃癌发病率的上升和医疗保健支出的增加将推动哥伦比亚整个市场的增长。
哥伦比亚胃癌药物 市场范围和市场规模
哥伦比亚胃癌药物市场根据类型、阶段、治疗、给药途径、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据类型，市场分为腺癌、淋巴瘤、胃肠道间质瘤、类癌瘤等。由于哥伦比亚胃癌治疗市场在药物生产方面投入了过多研发，预计 2022 年腺癌治疗领域将占据该市场主导地位。
- On the basis of stage, the market is segmented into stage I, stage II, stage III, stage IV, and others. In 2022, the stage III segment is expected to dominate the Colombia gastric cancer drugs market as this stage spreads very quickly and delayed diagnosis of gastric cancer leads the stages of cancer which is the reason behind stage III dominance.
- On the basis of treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others. In 2022, the chemotherapy segment is expected to dominate the Colombia gastric cancer treatment market due to the increasing adoption of Chemotherapy with other treatment methods.
- On the basis of route of administration, the market is segmented into oral and parenteral. In 2022, the parenteral segment is expected to dominate the Colombia gastric cancer drugs market due to high bioavailability of parenteral dosage form along with that most of the product available in the market for gastric cancer of in parenteral form.
- On the basis of end user, the market is segmented into speciality clinics, hospitals, research and academic institutes, and others. In 2022, the hospitals segment is expected to dominate the Colombia gastric cancer drugs market as hospitals in Colombia are building comprehensive cancer care centers and are the primary source of healthcare in Colombia.
- On the basis of distribution channel, the market is segmented into retail pharmacy, hospital pharmacy, and others. In 2022, the hospital pharmacy segment disease segment is expected to dominate the Colombia gastric cancer drugs market due to the fact that the gastric cancer patients generally patients prefer hospitals for better care.
Growing Strategic Activities by Major Market Players to Enhance Awareness for Gastric Cancer to Boost the Market Growth
The Colombia Gastric cancer drugs market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for the period 2020 to 2029.
Competitive Landscape and Colombia Gastric Cancer Drugs market Share Analysis
Colombia gastric cancer drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Colombia gastric cancer drugs market
在哥伦比亚胃癌药物市场经营的一些主要公司包括拜耳公司、诺华公司、辉瑞公司、Celltrion Healthcare Co.,Ltd.、F. Hoffmann-La Roche Ltd、默克公司、Teva Pharmaceutical Industries Ltd.、赛诺菲、阿斯利康、Viatris Inc.、百时美施贵宝公司、Concord Biotech 和葛兰素史克公司等。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
世界各地的公司也签订了许多合同和协议，进一步加速了哥伦比亚胃癌药物市场的增长。
例如，
- 2018 年 4 月，Celltrion Healthcare 宣布已扩大与制药供应商 Mundipharma 的合作伙伴关系，以在哥伦比亚授权、营销和分销其癌症治疗药物 Truxima。
- 2020 年 11 月，辉瑞公司宣布其 Upjohn 部门与 Mylan NV 合并，成立了一家名为 Viatris 的新公司。该公司业务部门与 Mylan NV 的合并增加了其产品组合，从而增加了市场对其产品的需求
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF COLOMBIA GASTRIC CANCER DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 COLOMBIA GASTRIC CANCER DRUGS MARKET: REGULATORY SCENARIO
6 SUMMARY WRITE UP (COLOMBIA)
6.1 OVERVIEW
7 PIPELINE ANALYSIS FOR COLOMBIA GASTRIC CANCER DRUGS MARKET
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROWING GASTRIC CANCER BURDEN WORLDWIDE
8.1.2 GROWING GERIATRIC POPULATION
8.1.3 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANISATIONS
8.1.4 RISING NUMBER OF PRODUCT APPROVALS
8.2 RESTRAINTS
8.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH GASTRIC CANCER TREATMENT DRUGS
8.2.2 LACK OF EARLY DETECTION OF GASTRIC CANCER
8.3 OPPORTUNITIES
8.3.1 RECENT ADVANCEMENTS IN GASTRIC CANCER TREATMENT
8.3.2 ADOPTION OF AUTOMATED SYSTEMS
8.3.3 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.4 CHALLENGES
8.4.1 CHALLENGE RELATED TO COLOMBIAN HEALTHCARE
8.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES
9 IMPACT OF COVID-19 PANDEMIC ON COLOMBIA GASTRIC CANCER DRUGS MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TYPE
10.1 OVERVIEW
10.2 ADENOCARCINOMA
10.3 GASTROINTESTINAL STROMAL TUMOR
10.4 CARCINOID TUMOR
10.5 LYMPHOMA
10.6 OTHERS
11 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY STAGES
11.1 OVERVIEW
11.2 STAGE III
11.3 STAGE II
11.4 STAGE IV
11.5 STAGE I
11.6 OTHERS
12 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TREATMENT
12.1 OVERVIEW
12.2 CHEMOTHERAPY
12.2.1 CISPLATIN
12.2.2 OXALIPLATIN
12.2.3 FLUOROURACIL
12.2.4 DOCETAXEL
12.2.5 CAPECITABINE
12.2.6 CARBOPLATIN
12.2.7 EPIRUBICIN
12.2.8 PACLITAXEL
12.2.9 IRINOTECAN
12.2.10 OTHERS
12.3 TARGETED THERAPY
12.3.1 MONOCLONAL ANTIBODY THERAPY
12.3.1.1 TRASTUZUMAB (HERCEPTIN)
12.3.1.2 RAMUCIRUMAB
12.3.2 MULTIKINASE INHIBITORS
12.3.2.1 SUNITINIB
12.3.2.2 REGORAFENIB
12.4 IMMUNE CHECKPOINT INHIBITORS
12.5 OTHERS
13 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 PARENTERAL
13.2.1 INTRAVENOUS
13.2.2 SUBCUTANEOUS
13.2.3 OTHERS
13.3 ORAL
13.3.1 TABLET
13.3.2 CAPSULE
13.3.3 OTHERS
13.4 OTHERS
13.5 OVERVIEW
13.6 HOSPITALS
13.7 SPECIALITY CLINICS
13.8 RESEARCH & ACADEMIC INSTITUTES
13.9 OTHERS
14 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 OTHERS
15 COLOMBIA GASTRIC CANCER DRUGS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 F.HOFFMAN-LA ROCHE
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.1.4.1 AGREEMENT
17.2 MERCK KGAA (A SUBSIDIARY OF MERCK & CO., INC.)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENTS
17.2.4.1 PRODUCT APPROVAL
17.2.4.2 EVENTS
17.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.3.4.1 COLLABORATION
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.4.4.1 ACQUISITION
17.5 ASTRAZENECA
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.5.4.1 PRODUCT APPROVAL
17.6 BAYER AG
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.6.4.1 COLLABORATION
17.7 BRISTOL-MYERS SQUIBB COMPANY
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.7.4.1 PRODUCT APPROVAL
17.8 CELLTRION HEALTHCARE CO., LTD.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.8.4.1 PRODUCT APPROVAL
17.9 CONCORD BIOTECH.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 GLAXOSMITHKLINE PLC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.10.4.1 PRODUCT APPROVAL
17.11 NOVARTIS AG
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.11.4.1 PRODUCT LAUNCH
17.12 PFIZER INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.12.4.1 MERGER
17.12.4.2 COLLABORATION
17.13 VIATRIS INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 3 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 4 COLOMBIA CHEMOTHERAPY IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 5 COLOMBIA TARGETED THERAPY IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 6 COLOMBIA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 7 COLOMBIA MULTIKINASE INHIBITORS IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 8 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 9 COLOMBIA PARENTRAL IN GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 10 COLOMBIA ORAL IN GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 11 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 12 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 COLOMBIA GASTRIC CANCER DRUGS MARKET: SEGMENTATION
FIGURE 2 COLOMBIA GASTRIC CANCER DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 COLOMBIA GASTRIC CANCER DRUGS MARKET: DROC ANALYSIS
FIGURE 4 COLOMBIA GASTRIC CANCER DRUGS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 COLOMBIA GASTRIC CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 COLOMBIA GASTRIC CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 COLOMBIA GASTRIC CANCER DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 8 COLOMBIA GASTRIC CANCER DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 COLOMBIA GASTRIC CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 COLOMBIA GASTRIC CANCER DRUGS MARKET: END USER OVERAGE GRID
FIGURE 11 COLOMBIA GASTRIC CANCER DRUGS MARKET: SEGMENTATION
FIGURE 12 INCREASING IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA AND ADENOCARCINOMA AND HIGH PREVALENCE OF OBESITY ARE EXPECTED TO DRIVE THE COLOMBIA GASTRIC CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE COLOMBIA GASTRIC CANCER DRUGS MARKET IN 2022 & 2029
FIGURE 14 REGULATORY PROCESS OF DRUGS AND BIOLOGICS APPROVAL IN COLOMBIA
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF COLOMBIA GASTRIC CANCER DRUGS MARKET
FIGURE 16 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TYPE, 2021
FIGURE 17 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 18 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY STAGES, 2021
FIGURE 21 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY STAGES, 2020-2029 (USD MILLION)
FIGURE 22 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 23 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 24 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TREATMENT, 2021
FIGURE 25 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TREATMENT, 2020-2029 (USD MILLION)
FIGURE 26 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 27 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 28 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY ROUTE OF AMINISTRATION, 2021
FIGURE 29 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 30 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY ROUTE OF AMINISTRATION, CAGR (2022-2029)
FIGURE 31 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY ROUTE OF AMINISTRATION, LIFELINE CURVE
FIGURE 32 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY END USERS, 2021
FIGURE 33 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY END USERS, 2020-2029 (USD MILLION)
FIGURE 34 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY END USERS, CAGR (2022-2029)
FIGURE 35 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY END USERS, LIFELINE CURVE
FIGURE 36 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 37 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 38 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 39 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 COLOMBIA GASTRIC CANCER DRUGS MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
